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Abstract 
Inactivation of APC is a strongly predisposing event in the development of colorectal 
cancer
1,2
, prompting us to search for vulnerabilities specific to cells that have lost APC 
function. Signalling through the mTOR pathway is known to be required for epithelial cell 
proliferation and tumour growth
3-5
 and the current paradigm suggests that a critical function 
of mTOR activity is to upregulate translational initiation through phosphorylation of 
4EBP1
6,7
. This model predicts that the mTOR inhibitor rapamycin, which does not efficiently 
inhibit 4EBP1
8
, would be ineffective in limiting cancer progression in APC deficient lesions. 
Here we show that mTORC1 activity is absolutely required for the proliferation of APC 
deficient (but not wild type) enterocytes, revealing an unexpected opportunity for therapeutic 
intervention. Although APC deficient cells show the expected increases in protein synthesis, 
our studies reveals that it is translation elongation, and not initiation, which is the rate-
limiting component. Mechanistically, mTORC1 mediated inhibition of eEF2 kinase is 
required for the proliferation of APC deficient cells. Importantly, treatment of established 
APC deficient adenomas with rapamycin (which can target eEF2 through the mTORC1 – 
S6K – eEF2K axis) causes tumour cells to undergo growth arrest and differentiation. Taken 
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together our data suggest that inhibition of translation elongation using existing, clinically 
approved drugs such as the Rapalogs, would provide clear therapeutic benefit for patients at 
high-risk of developing colorectal cancer.  
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Main Text 
The ability of the intestinal epithelium to regenerate following challenge has been well 
described
9-11
. We have shown that this is a Wnt-driven process that mimics the proliferation 
observed following Apc deletion
11,12
 and is a valuable model of the early stages of intestinal 
cancer. However, the underlying mechanisms controlling these processes are largely 
unknown. The serine/threonine kinase mTOR, particularly the mTOR Complex 1 
(mTORC1), is a known mediator of cell growth and proliferation
13
. Previous studies have 
suggested that mTORC1 may be important in both the intestinal stem-cell niche and for 
intestinal tumourigenesis
4,5,14
. We therefore queried the role of mTORC1 in intestinal 
proliferation following Wnt activation. Following Apc deletion there was an increase in the 
phosphorylation status of mTORC1 effectors rpS6 and 4EBP1 that was dependent on MYC 
expression. Increased phosphorylation of these proteins was also seen during crypt 
regeneration (Fig. 1a,b,c, Extended Data Fig. 1a). Importantly, the mTOR inhibitor 
rapamycin blocked intestinal regeneration, demonstrating that mTOR signalling is required 
for this process (Fig. 1d,e). Given that rapamycin did not affect apoptosis nor proliferation in 
the normal intestine (Extended Data Fig. 1b,c), these data suggest that there may be a 
potential therapeutic window, between normal intestinal enterocytes and those with a high 
level of Wnt activity. Therefore Raptor (an essential component of mTORC1) was deleted in 
the intestinal epithelium (Extended Data Fig. 1d). Surprisingly, normal gut homeostasis was 
unaffected by Raptor loss 4 days post-Cre induction, when using an epithelium-specific Cre-
Recombinase (VillinCRE
ER
 Rptor
fl/fl
) (Extended Data Fig. 1e,f). Furthermore, 400 days after 
induction, no phosphorylation of rpS6 or 4EBP1 was observed, showing that Raptor deletion 
was sustained (Extended Data Fig. 2a). Raptor loss caused no change in either levels of 
mitosis or apoptosis (Extended Data Fig. 2b,c) but proved to be essential for the proliferative 
phenotype observed during regeneration or following Apc deletion (Fig. 1a,b,d,e,f). Nuclear 
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localisation of β-catenin and high levels of MYC could be demonstrated by IHC, showing 
that Wnt-activation is still present (Extended Data Fig. 3a,b).  
 
Given that rapamycin treatment and Raptor deletion had similar effects, we examined 
whether rapamycin treatment was sufficient to modify intestinal tumourigenesis, either 
prophylactically, or chemotherapeutically. First we assessed whether rapamycin could 
suppress a model of intestinal tumourigenesis, in which Apc deletion is targeted to LGR5-
positive stem cells using the LGR5CRE
ER
 (LGR5CRE
ER
 Apc
fl/fl
). Mice were treated starting 10 
days post-Cre induction, and in contrast to controls, remained tumour free for the duration of 
the experiment (Fig. 2a,b). Next we treated mice (Apc
Min/+
 or LGR5CRE
ER
 Apc
fl/fl
) with 
established adenomas. Remarkably, the mice lost their clinical symptoms of disease and 
survived significantly longer than controls (Fig. 2c,d; Extended Data Fig. 4a).  We next 
analysed the tumours from these mice over a time-course post-rapamycin treatment. 
Treatment caused a loss of proliferation specifically within the tumours by 72-hours, and an 
increase in the number of Lysozyme-positive paneth cells (Fig. 2e; Extended Data Fig. 4b,c). 
By 30 days, most tumours had shrunk considerably to small non-proliferative lesions that no 
longer contained paneth cells (Fig. 2f; Extended Data Fig. 4d). Within the normal intestine 
there are two main cell populations that show high levels of Wnt-signalling; the label-
retaining/progenitor population and the paneth cell population
15
.  Our data suggest that 
treatment of mice with rapamycin causes the differentiation of the tumour’s Wnt-high 
progenitor cells into the other Wnt-high fate in the intestine; namely non-proliferative paneth-
like cells. The cell-cycle arrest in these cells was examined by staining for p21, p16, p53. No 
increase in these markers was observed, suggesting a classical cell cycle arrest pathway had 
not been engaged (Extended Data Fig. 5a). We reasoned that if mice were removed from 
rapamycin the tumours would regain proliferative capacity. Indeed, when rapamycin 
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treatment was halted, signs of intestinal neoplasia were observed approximately 40–60 days 
later (Extended Data Fig. 4a). This suggested that intestinal adenoma stem cells were still 
present. Tumours from LGR5-GFP-CRE
ER
 mice were stained to detect LGR5-GFP positivity. 
We found that following rapamycin treatment, numerous LGR5-positive cells were still 
present, indicating that, while rapamycin treatment causes a regression of the lesions, the 
tumour initiating cells remain (Extended Data Fig. 5b).  
 
We examined the mechanism of mTORC1 requirement following Apc loss. mTORC1 is 
known to regulate protein synthesis on multiple levels and most research has focused on two 
downstream effectors: 4EBP1 and S6K. A number of studies have suggested that translation 
initiation, via the 4EBP1 – eIF4E axis, is the critical effector of mTOR in cancer6,16. 
However, it has been shown that rapamycin preferentially inhibits the phosphorylation of 
S6K over 4EBP1
8
, suggesting that 4EBP1-mediated inhibition of translation initiation may 
not be limiting in the context of Apc loss. To assess the changes in translational control in 
response to mTORC1 inhibition, we measured the polysomal distribution in WT, Apc-
deficient and Apc/Raptor-deficient intestinal epithelial cells 4-days post gene deletion. Apc 
deletion resulted in a decrease in the number of polysomes, whereas Apc/Raptor co-deletion 
reversed this effect (Fig. 3a). The decrease in the number of polysomes following Apc 
deletion could suggest either reduced translation initiation (and consequently a lower overall 
level of translation) and/or a faster rate of translational elongation. Global translation rates 
were measured using an in vitro intestinal crypt 3d-culture model
17
. The Apc-deficient cells 
were shown to have increased 
35
S-labelled methionine/cysteine incorporation compared to 
WT, showing higher overall levels of protein synthesis (Fig. 3b). Unfortunately, Raptor 
deletion prevented the growth of crypts in vitro so this could not be assayed (Extended Data 
Fig. 6).  
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To measure the rate of translational elongation, an in vitro harringtonine run-off assay was 
performed
18
, as described in Supplementary Materials and Methods. There was a >2.5-fold 
increase in ribosome run-off in crypts with Apc deletion compared to wild-type (Fig. 3c; 
Extended Data Fig. 7). This suggests that following Wnt activation, elongation, rather than 
initiation, is rate limiting for protein synthesis and mTORC1 must be activated to overcome 
this. 
 
Cycloheximide (an inhibitor of elongation
19
) reduced proliferation associated with Apc 
deletion, to a similar level to rapamycin (Extended Data Fig. 8). While cycloheximide is 
acknowledged to inhibit elongation
19
, it must be emphasised that 72hr treatment could result 
in broad alterations in protein synthesis. However, the Apc
fl/fl
-specific loss of proliferation 
observed here provides “proof of principle” to demonstrate that modulation of protein 
synthesis may be useful as a chemotherapeutic strategy.   
 
As most previous work has suggested translation initiation downstream of 4EBP1 is limiting 
to cancer
20
, it was important to probe known effectors of mTORC1 in this system. Given the 
alteration of elongation rates, the elongation factor 2 kinase (eEF2K), a known target of 
S6K
21,22
 was of particular interest. eEF2K is a negative regulator of the elongation factor 2 
(eEF2), giving mTORC1 the ability to promote translational elongation via S6K
23
. Using 
multiple mouse knockout and knock-in alleles, we further dissected the downstream effectors 
of mTORC1 in intestinal regeneration. S6k1/2 knockout decreased intestinal regeneration, 
whilst knockout of Eif4ebp1/2 had no effect. As the 4EBP proteins are negative regulators of 
eIF4E, an increase (rather than decrease) in regeneration may have been predicted, but this 
was not found. Moreover these intestines were still sensitive to rapamycin, demonstrating that 
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rapamycin was acting via the mTORC1-S6K branch rather than 4EBP1-eIF4E (Extended 
Data Fig. 9). We then used an Eef2k-null mouse and showed that following irradiation and 
treatment with rapamycin, these mice were now resistant to mTORC1 inhibition, confirming 
the importance of translational elongation (Fig. 4a). To ensure that S6K was not also acting 
through its more established effector, rpS6, we used an rpS6 phospho-mutant that cannot be 
phosphorylated by S6K. This was unable to phenocopy Raptor deletion (Fig. 4a), showing 
that Wnt-driven regeneration requires increased translational elongation, mediated through 
mTORC1.   
 
To prove that inhibition of eEF2K by S6K is required to allow increased eEF2 activity 
following Apc loss, we intercrossed VillinCRE
ER
 Apc
fl/fl
 to Eef2k
-/-
 mice and treated these with 
rapamycin. In contrast to VillinCRE
ER
 Apc
fl/fl
 mice, these intestines were now resistant to 
growth inhibitory effects of rapamycin (Fig. 4b,c). Tellingly, these mice no longer show an 
increase in the inhibitory phosphorylation of eEF2 following rapamycin treatment (Extended 
Data Fig. 10).  
 
To assess whether the increased elongation following Apc deletion had differential affects on 
cell cycle regulating proteins, RNA and protein levels of several key cell cycle regulators 
were tested (Fig. 4d,e). This analysis revealed that whilst there were increased RNA and 
protein levels of Cyclin D1, D2, CDK4 and CDK6, Cyclin D3 had increased protein levels in 
the absence of increased mRNA levels. Cyclin D3 protein levels were sensitive to rapamycin 
exposure, and this sensitivity depends on eEF2K (Extended Data Fig. 11). Additionally, 
ribosomes were shown to elongate approximately 4-times faster on Cyclin D3 messages in 
Apc-deficient cells than WT cells. No differences were detected in other messages tested 
(Extended Data Fig. 12). Taken together, these data suggest that Cyclin D3 is translationally 
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regulated at the level of elongation, consistent with previous reports
24,25
. The contribution of 
Cyclin D3 to the proliferative phenotype remains to be elucidated. 
 
In summary, we report that mTORC1 is an essential downstream effector of Wnt-signalling 
in the intestine. We show that intestinal proliferation associated with Wnt-signalling requires 
the mTORC1 – S6K – eEF2K – eEF2 axis, and that the resulting increase in the rate of 
elongation of specific polypeptides overcomes a limiting translational step. Our work 
highlights key functional roles for eEF2K and translational elongation in the control of the 
initiation of cancer and adenomatous proliferation. The importance of elongation in this 
context has been suggested in a small number of publications, but this study provides 
definitive in vivo evidence
26-28
. Finally, we have also shown that targeting mTOR and 
translational control may be a viable strategy for chemoprevention of CRC in high risk 
patients, and treatment of early stage disease. Indeed, recent studies have suggested that the 
chemopreventative agents aspirin and mesalazine also target mTOR
29,30
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Figure 1: mTORC1 is essential for Wnt-driven proliferation in a MYC-dependent manner 
a+b) Representative IHC of phospho-rpS6 and phospho-4EBP1 showing increased staining 
96hrs following Apc deletion. Raptor deletion caused a loss of positivity in both, whereas 
10mg/kg rapamycin treatment (beginning at 24hrs) specifically disrupts rpS6 
phosphorylation; c) Representative IHC of phospho-rpS6 96hrs after Cre induction showing 
that Wnt-driven rpS6 phosphorylation is MYC dependent; d) Animals were exposed to 14Gy 
γ-irradiation and intestinal regeneration was measured 72hrs later, by counting the number of 
viable crypts and multiplying that by the average size of the regenerating crypts. Boxplot 
shows that 10mg/kg rapamycin treatment and Raptor deletion significantly decrease intestinal 
regeneration. Whiskers are max and min, black line is median (n=5 biological replicates per 
group; **p-value<0.02, Mann-Whitney U test); e) Representative H+E staining of 
regenerating intestines 72hrs after exposure to 14Gy γ-irradiation. Arrowheads indicate 
regenerating crypts; f) Representative H+E staining 96hrs after Apc loss, showing that 
10mg/kg rapamycin treatment or Raptor deletion prevent Wnt-driven proliferation. Treatment 
12 
 
began 24hrs after Apc deletion. Red bar is graphical representation of crypt size. Scale bar = 
100µm.  
Figure 2: Apc-driven tumourigenesis requires mTORC1 activation 
a+b) Graphical representation of prophylactic rapamycin treatment strategy and Kaplan-
Meyer survival curve showing that prophylactic rapamycin treatment prevents 
tumourigenesis. 10mg/kg rapamycin treatment began at Day 10 post-Apc deletion, and lasted 
30 days, after which mice were sampled. Area highlighted by red indicates duration of 
rapamycin treatment (n≥7; ***p-value≤0.001, Log Rank test); c+d) Graphical representation 
of chemotherapeutic rapamycin treatment strategy and Kaplan-Meyer survival curve showing 
that rapamycin treatment can regress established intestinal tumours. 10mg/kg rapamycin 
treatment started when mice showed signs of intestinal disease, and lasted 30 days, after 
which mice were sampled. Graph represents survival while on rapamycin treatment (n≥5; 
***p-value≤0.001, Log Rank test); e) Representative IHC of phospho-rpS6, BrdU and 
Lysozyme, showing that 72hrs of 10mg/kg rapamycin treatment causes a loss in rpS6 
phosphorylation and BrdU positivity, and an increase in lysozyme staining in intestinal 
tumours; f) Representative H+E and IHC for BrdU showing that small, non-proliferative 
lesions remain after 30 days of 10mg/kg rapamycin treatment. Scale bar = 100µm 
 
Figure 3: mTORC1 drives increased translational elongation 
a) Representative polysome profiles of intestinal epithelial cells showing altered RNA 
distribution 96hrs after Apc deletion. Bar graph represents the ratio of sub-polysomes 
compared to polysomes (S:P). Data are average ± s.e.m. (n≥3 per group; *p-value≤0.05, 
Mann-Whitney U test); b) Intestinal crypt culture was pulsed for 30 min with 
35
S-labelled 
methionine/cysteine. Incorporation of 
35
S into protein was quantified by scintillation counting 
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and normalized to total protein. Apc deletion increases 
35
S incorporation. Data are average ± 
s.e.m. (n=3 biological replicates per group; *p-value≤0.05, Mann-Whitney U test); c) The 
ribosome run-off rate was measured by addition of the initiation inhibitor harringtonine to ex 
vivo crypts from wild-type and Apc deleted mice. Harringtonine was added for 0 or 180 
seconds and the increase in sub-polysomes (S) relative to polysome (P) calculated. This run-
off rate represents the shift in S:P between the two time points, which is proportional to 
elongation speed. Data are average ± s.e.m. (n≥3 biological replicates per group; *p-
value≤0.05, Mann Whitney U test). Also see Supplemental Figure 7. 
 
Figure 4: mTORC1 signalling via eEF2K controls intestinal proliferation following Wnt-
signalling 
a) Graphical representation of findings and boxplots showing that murine intestinal 
regeneration following irradiation implicates the mTORC1-S6K-eEF2K axis in Wnt-driven 
proliferation. Animals were exposed to 14Gy γ-irradiation, and intestinal regeneration was 
calculated 72hrs after exposure, by examining the number and size of regenerating crypts, 
relative to WT regenerating intestines. Whiskers are max and min, black line is median (n=6 
per group; *p-value<0.05, NS: not significant, Mann-Whitney U test); b+c) Representative 
H+E and boxplot showing Eef2k deletion confers resistance to 10mg/kg rapamycin treatment, 
96hrs after Apc deletion. Treatment began 24hrs after induction. Red bar is graphical 
representation of crypt size. Whiskers are max and min, black line is median (n=3 biological 
replicates per group; *p-value<0.05, Mann-Whitney U test); d) qRT-PCR of intestinal 
epithelial cells using primers for Cdk4, Cdk6, Ccnd1, Ccnd2 and Ccnd3. Ccnd3 is not 
regulated at the transcriptional level. Data were normalised to Gapdh. Data are average ± 
s.e.m. (n=3 biological replicates per group, *p-value≤0.05, NS: not significant, Mann 
Whitney U test); e) Western blot analysis of intestinal epithelial cells from each group. 
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Antibodies to CDK4, CDK6, Cyclin D1, Cyclin D2, Cyclin D3 and β-actin are shown. Each 
well represents a different mouse from the relevant group, and are the same samples used for 
the qRT-PCR. Scale bar = 100µm. 
 
Extended Data Fig. 1: mTORC1 is activated following Wnt-signal and its inhibition does 
not affect homeostasis 
a) Reptesentative IHC of phospho-rpS6 and phospho-4EBP1 show mTORC1 activity during 
intestinal regeneration, 72hrs after 14Gy γ-irradiation; b+c) boxplots demonstrating that 
72hrs of 10mg/kg rapamycin treatment does not alter mitosis or apoptosis in normal intestinal 
crypts. Whiskers are max and min, black line is median (n=4 per group; NS: not significant, 
Mann-Whitney U test); d) Intestines imaged on OV100 microscope, 96hrs post induction, for 
RFP. Tissue without the ROSA-tdRFP reporter (labelled Neg Control) show no RFP 
positivity, while the positive control and Raptor fl/fl
 
intestines show high RFP positivity; e+f) 
boxplot showing that Raptor deletion does not affect mitosis or apoptosis rates in intestinal 
crypts, 96hrs after induction. Whiskers are max and min, black line is median (n=4 per group; 
NS: not significant, Mann-Whitney U test). Scale bar = 100µm 
Extended Data Fig. 2: Raptor deletion is maintained in the small intestine 
a) Representative IHC of phospho-rpS6 and phospho-4EBP1 shows maintained loss of 
mTORC1 signalling 400+ days after Raptor deletion. Arrows indicate unrecombined escaper 
crypts that still show active mTORC1 signalling; b+c) boxplots showing that mitosis and 
apoptosis are unchanged 400+ days after Raptor deletion. Mitosis and apoptosis were counted 
on H+E sections and are quantified as percent mitosis or apoptosis per crypt. Whiskers are 
max and min, black line is median (n=5 per group; NS: not significant, Mann-Whitney U 
test). Scale bar = 100µm 
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Extended Data Fig. 3: Wnt-signalling is still active after Raptor deletion 
a+b) Representative IHC of MYC and β-catenin showing high MYC levels and nuclear 
localisation of β-catenin 96hrs after Apc and Apc/Raptor deletion, demonstrating active Wnt-
signalling. Nuclear staining (as opposed to membranous staining) of β-catenin is indicative of 
active Wnt-signalling; Scale bar = 100µm 
 
Extended Data Fig. 4: Rapamycin treatment causes regression of established tumours 
a) Kaplan-Meyer survival curve of Apc
Min/+
 mice treated with rapamycin when showing signs 
of intestinal neoplasia. 10mg/kg rapamycin treatment started when mice showed signs of 
intestinal disease, and was withdrawn after 30 days. Animals continued to be observed until 
signs of intestinal neoplasia. Death of animals in the rapamycin group almost always 
occurred following rapamycin withdrawal. (n=8 per group, ***p-value≤0.001, Log Rank 
test); b) boxplot showing that 72hr 10mg/kg rapamycin treatment causes an increase in 
Lysozyme positive cells in tumours. Percent Lysozyme positivity within tumours was 
calculated using Image J software (http://imagej.nih.gov/ij/). Whiskers are max and min, 
black line is median (10 tumours from each of 5 mice per group were measured, **p-
value≤0.014, Mann-Whitney U test); c) boxplot showing that 72hrs 10mg/kg rapamycin 
treatment causes a decrease in BrdU positivity within tumours. Percent BrdU positivity 
within tumours was calculated using Image J software. Whiskers are max and min, black line 
is median (10 tumours from each of 5 mice per group were measured, **p-value≤0.021, 
Mann-Whitney U test); d) Representative IHC of Lysozyme, showing a lack of Lysozyme 
positive paneth cells in remaining cystic tumours after 30 days of 10mg/kg rapamycin 
treatment; Scale bar = 100µm. 
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Extended Data Fig. 5: IHC following rapamycin treatment 
a) Representative IHC of p21, p16, and p53 after 6hrs and 72hrs of 10mg/kg rapamycin 
treatment. Staining shows no induction of these proteins in tumours following rapamycin 
treatment; b) Representative IHC for LGR5 GFP showing high numbers of LGR5-positive 
cells after 7 and 30 days of 10mg/kg daily rapamycin treatment. Scale bar = 100µm 
Extended Data Fig. 6: Raptor deletion in the intestinal crypt 
a) Graph showing that Raptor deletion prevents intestinal crypts from growing ex vivo. 
Intestinal crypts were isolated and cultured as previously described
17
, 96hrs after Cre 
induction. Number of viable organoids was counted by eye 72hrs after crypt isolation. Data 
are average ± s.d. (n=3 biological replicates per group). 
Extended Data Fig. 7: Apc deletion increases translational elongation rates 
a) Representative polysome profiles from wild-type ex vivo crypts incubated with 
harringtonine for 0 seconds (left) and 180 seconds (right) prior to harvest. b) The areas under 
the sub-polysome (40S, 60S and 80S) and polysome sections as indicated by the dashed lines 
in a) were quantified and expressed as a percentage of their sum. Data in the bar graph is the 
average ± s.e.m (n=3 per time point). c) and d) show data for Apc deleted crypts as for wild-
type in a) and b). (n=3 biological replicates). 
 
Extended Data Fig. 8: Cycloheximide treatment phenocopies rapamycin treatment 
a) Representative H+E showing that 35mg/kg cycloheximide treatment phenocopies 
rapamycin treatment 96hrs after Apc deletion. Treatment began 24hrs after induction; b) 
Representative IHC for BrdU showing a loss of proliferation in tumours after 72hrs of 
35mg/kg cycloheximide treatment. Arrow highlights normal proliferating crypts. Scale bar = 
100µm 
17 
 
 
Extended Data Fig. 9: S6k deletion decreases intestinal regeneration 
Graphical representation of findings, and boxplot showing that murine intestinal regeneration 
following irradiation is dependent on S6K. Animals were exposed to 14Gy γ-irradiation, and 
intestinal regeneration was calculated 72hrs after exposure by counting the number of viable 
crypts and multiplying that by the average size of the regenerating crypts. Relative 
regeneration was calculated by comparing each group to WT regeneration. Rapamycin 
treatment arm is reproduced from Fig.4 for visual clarity. Whiskers are max and min, black 
line is median (n=6 per group, *p-value=0.034, Mann Whitney U test). 
Extended Data Fig. 10: Eef2k deletion drives resistance to rapamycin 
a) Representative IHC of phospho-eEF2 and phospho-S6 in WT,  Apc-deficient and Apc- and 
Eef2k-deficient (with and without 72hrs 10mg/kg rapamycin treatment) shows that rapamycin 
is unable to induce eEF2 phosphorylation in the absence of eEF2K. Scale bar = 100µm 
Extended Data Fig. 11: Cyclin D3 is regulated at the level of elongation 
a) Representative IHC of Apc
fl/fl
 intestines with and without Eef2k deletion. Antibodies to 
eEF2K, phospho-S6, and Cyclin D3 are shown. Following Eef2k KO, Cyclin D3 levels are no 
longer decreased upon 10mg/kg rapamycin treatment; b) boxplot showing the number of 
Cyclin D3 positive cells per crypt, 96hrs after Apc deletion, with and without 10mg/kg 
rapamycin treatment. Graph shows that in Eef2k KO animals, rapamycin no longer reduced 
Cyclin D3 levels (n≥3 biological replicates per group; *p-value≤0.05, Mann Whitney U test); 
c) western blot analysis of intestinal epithelial cells from Apc
fl/fl
 and Apc
fl/fl
 Eef2k KO, with 
and without 10mg/kg rapamycin . Antibodies to eEF2K, phospho-S6, Cyclin D3 and β-actin 
are shown. Each well represents a different mouse from the relevant group. Cyclin D3 levels 
are no longer reduced following Eef2k deletion. Scale bar = 100µm.  
18 
 
Extended Data Fig. 12: Ribosomes elongate faster on Ccnd3 following Apc deletion 
The ribosome run-off rate of various messages was measured as in Figure 3. Elongation of 
Ccnd3 was significantly increased, while Actb, Rps21, Rps6 and Ccnd1 remain unchanged.  
Data are average ± s.e.m. (n≥3 biological replicates per group; *p-value≤0.05, Mann Whitney 
U test). 
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